Health Care • Medical Specialities
$69.30 ▼ -0.16
(-0.23%)
MKT CAP: $3.39B • VOL: 820.7K
52W L $54 52W H $151
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
CELC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$172.2M | -$113.3M | -$66.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$177.0M | -$111.8M | -$63.8M |
| EBITDA (Normalized) | -$172.0M | -$113.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$153.3M | -$83.5M | -$53.8M |
| Capital Expenditures (CapEx) | $249.0K | $250.0K | — |
| Free Cash Flow (FCF) | -$153.5M | -$83.7M | -$53.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $165.7M | $22.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $100.6M | $115.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CELC.